Corgi IP Licensing and Royalties ETF (PTNT)
Live price chart, market sentiment, and community perspectives for Corgi IP Licensing and Royalties ETF (CBOE: PTNT).
Live price chart, market sentiment, and community perspectives for Corgi IP Licensing and Royalties ETF (CBOE: PTNT).
On our desk, we are looking closely at the macro premise behind PTNT. Ocean Tomo data cited by Corgi Funds shows that intangible assets now represent 92.00% of SandP 500 market capitalization, up dramatically from 17.00% in 1975. This secular trend strongly justifies dedicated thematic exposure to IP monetization, even if near-term price action is sluggish.
In our quantitative framework assessing the Corgi ETF Trust I filing (Form N-1A), PTNT's structure as a non-diversified equity ETF with a 0.35% expense ratio provides targeted access to precious metals streaming and royalty structures. However, risk managers must account for the 52-week range between $25.28 and $28.06 and light initial assets totaling roughly $1.45 million.
Watching the technicals on PTNT, the summary flashes a 'Strong Sell' across multiple short-term frames with an RSI sitting at 43.60. While the underlying thesis targeting wireless patent holders, pharma royalty aggregators, and semiconductor architecture licensing is robust, liquidity remains a constraint with a 3-month average volume under 1,700 shares.
From a bio-analyst perspective, the inclusion of pharmaceutical royalty aggregators inside PTNT offers a unique defensive posture against clinical trial binary outcomes. Instead of betting on a single phase 3 drug, the fund captures diversified top-line drug royalty streams, though overall portfolio correlation to broader equity sell-offs remains a factor to hedge.
As a hedge fund portfolio manager evaluating niche thematic vehicles, the launch of PTNT on Cboe BZX captures record global patent applications hitting 3.7 million. The fund's active management approach targeting per-device wireless royalties and semiconductor IP core designers gives it a differentiated factor profile relative to standard cap-weighted tech indexes.
On the options desk, we've tracked periodic option listings and delistings for PTNT since May 2026. Given the narrower average trading volumes and non-diversified nature of the underlying 30 holdings, option market-makers are maintaining wider bid-ask spreads until secondary market liquidity deepens substantially.
Explore plasma cleansing, somatic organ swaps, and BCI.